Evidence map›Paper›PMID 40046636›Full record

ArticleOncology letters2025

Pan‑immune‑inflammatory values predict survival in patients after radical surgery for non‑metastatic colorectal cancer: A retrospective study.

Kejin Li, Xiangyue Zeng, Ziyi Zhang, Kuan Wang, Yipeng Pan, Zhimin Wu, Yi Chen, Zeliang Zhao

Abstract read
In one paragraph

Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. The role of CSTF2 in gastric cancer: implications for therapy.European journal of medical research · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kejin LiDepartment of Gastrointestinal Surgery, The Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region 830000, P.R. China.
Xiangyue ZengDepartment of Gastrointestinal Surgery, The Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region 830000, P.R. China.
Ziyi ZhangDepartment of Gastrointestinal Surgery, The Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region 830000, P.R. China.
Kuan WangDepartment of Gastrointestinal Surgery, The Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region 830000, P.R. China.
Yipeng PanDepartment of Gastroenterology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310020, P.R. China.
Zhimin WuGuiyang Maternal and Child Health Care Hospital, Guiyang Children's Hospital, Guiyang, Guizhou 550003, P.R. China.
Yi ChenDepartment of Breast and Thyroid Surgery, The Affiliated Cancer Hospital of Xinjiang Medical University, Xinjiang Key Laboratory of Oncology, Urumqi, Xinjiang Uygur Autonomous Region 830000, P.R. China.
Zeliang ZhaoDepartment of Gastrointestinal Surgery, The Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region 830000, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study aimed to further investigate the predictive value of pan-immune-inflammatory values (PIVs) in patients with non-metastatic colorectal cancer after radical surgery. Additionally, the study sought to develop a predictive scoring model to predict the survival of patients with colorectal cancer after surgery. A total of 470 non-metastatic patients who attended The Affiliated Cancer Hospital of Xinjiang Medical University (Urumqi, China) for radical colorectal cancer surgery were retrospectively collected based on specific inclusion and exclusion criteria. Patients were categorized into the Low-PIV group and the High-PIV group according to the optimal cut-off value of PIV and a survival analysis was performed. Cox regression was performed for one-way multifactorial analysis. After independent risk factors were screened, a simple score prediction model was constructed and evaluated. The study indicated that PIV was significantly associated with the T stage, Tumor-Node-Metastasis stage, differentiated degree and nerve invasion (all P<0.05). Survival tanalysis showed that patients in the Low-PIV group had a significantly higher 5-year overall survival (OS) rate compared with those in the High-PIV group (88.7 vs. 46.3%; P<0.001). Through multifactorial Cox regression analysis, N stage [hazard ratio (HR), 2.00; 95% confidence interval (CI), 1.04-3.84; P=0.039], differentiated degree (HR, 1.98; 95% CI, 1.16-3.38; P=0.012), neutrophil/lymphocyte ratio (HR, 4.00; 95% CI, 2.19-7.29; P<0.001) and PIV (HR, 4.12; 95% CI, 2.04-8.32; P<0.001) were found to be independent predictors of OS. These variables were included in a column chart to create a scoring system. The concordance index was 0.789 (95% CI, 0.746-0.832). The 1-, 3- and 5-year calibration curves for this column-line diagram demonstrated high confidence. The area under the curve of the predictive model for 1-, 3- and 5-year OS were 0.823, 0.845 and 0.845, respectively. PIV was shown to be a reliable biomarker for the prognosis of patients with non-metastatic colorectal cancer. The current simple predictive scoring model can predict the effective survival of patients following radical surgery for non-metastatic colorectal cancer and could therefore play a substantial role in clinical decision-making.

Indexed as

colorectal cancernomogramoverall survivalpan-immune-inflammatory valueprognosis

Identifiers

PMID40046636
PMCPMC11880885

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.